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A B S T R A C T
Analysis of bodily fluids using vibrational spectroscopy has attracted increasing attention in recent years. In
particular, infrared spectroscopic screening of blood products, particularly blood serum, for disease diagnostics has
been advanced considerably, attracting commercial interests. However, analyses requiring quantification of
endogenous constituents or exogenous agents in blood are less well advanced. Recent advances towards this end are
reviewed, focussing on infrared and Raman spectroscopic analyses of human blood serum. The importance of
spectroscopic analysis in the native aqueous environment is highlighted, and the relative merits of infrared
absorption versus Raman spectroscopy are considered, in this context. It is argued that Raman spectroscopic analysis
is more suitable to quantitative analysis in liquid samples, and superior performance for quantification of high and
low molecular weight components, is demonstrated. Applications for quantitation of viral loads, and therapeutic
drug monitoring are also discussed.
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1. Introduction
Although concepts of biomedical applications of vibrational spectros-
copy have been discussed for more than three decades, and numerous
studies have demonstrated feasibility in, for example, histological and
cytological studies, clinical translation has been slow, prompting
consideration of achievable, strategic targets [1,2]. In this context,
applications for bodily fluid analysis have attracted increasing attention
over the past [3,4]. In a general clinical context, bodily fluids (e.g. plasma,
serum, saliva or urine) are emerging as an important source of samples for
disease diagnosis and therapeutic monitoring, as their collection is
relatively simple, largely non-invasive, and cost effective [5–9].
Blood plasma/serum remains the primary clinical specimen of
interest, and has been studied even before genes were known to exist
[10]. It contains more than 300 types of proteins, as well as
carbohydrates, lipids and amino acids, and up to 114,000 known
metabolites at varying concentrations [11]. As well as a rich source of
biomarkers for disease diagnostics, imbalances in endogenous plasma/
serum constituents themselves are of considerable clinical importance. In
the high molecular weight fraction (HMWF), levels of albumin, the most
abundant plasma protein, are typically elevated in cases of acute
hydration [12], and decrease dramatically in critically ill patients
(hypoalbuminaemia) [13], in sepsis and after major surgical stress
[14,15]. Many clinical studies have associated elevated levels of
fibrinogen in patients stroke [16] with cardiovascular disease [17,18]
and thrombosis and pulmonary embolism [19]. Variations of levels of
lower molecular weight fraction (LMWF) constituents such as glucose,
must be monitored on a regular basis in the case of diabetes patients [20],
and urea, are important for evaluating kidney or liver function, and even
heart failure [21–23]. Quantitation of exogenous agents such as viral
loads can be critical for assessing the severity of an active viral infection,
prognosis and to guide antiviral therapy [24]. Therapeutic dose
monitoring (TDM) in the blood stream is becoming increasingly
important to understand the pharmacokinetics of chemotherapeutic
agents and to individualise dose regimens per patient [25].
Blood collection is a routine clinical process which is largely
standardised, although some variations in collection protocols can occur.
For blood plasma collection, differing anticoagulants, including heparin
and Ethylenediaminetetraacetic acid (EDTA), are used in order to prevent
blood clotting. It has been shown, however, that the choice of
anticoagulant is noticeable in the resultant infrared spectrum, which
may conceal underlying biological [26,27]. The poorly soluble protein,
fibrinogen, has also been seen to cause a large scattering background in
Raman measurements of liquid samples [28,29]. For this reason, many
spectroscopic studies have been conducted on human serum, rather than
plasma samples.
There have been a number of reviews in the recent past of vibrational
spectroscopic analysis of biofluids, particularly with a view towards
clinical applications [4,30–32]. In the following, a review of the
methodologies specifically for quantitative analysis of blood serum
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constituents using both infrared absorption and Raman spectroscopies is
presented, drawing in particular from the experience of the authors, to
assess challenges and highlight developments in the field. Clinically
relevant imbalances in endogenous constituent components, such as high
molecular weight proteins, as well as low molecular weight constituents
such as glucose and urea are considered. Potential clinical applications in
monitoring viral loads and therapeutic drug monitoring are discussed.
2. Materials and methods
Specific examples of experimental data are drawn from previously
published work, with appropriate reference and copyright permissions.
Summary details are provided below. In the case where measurements of
human patient samples are referred to, specifics of compliance with the
Code of Ethics of the World Medical Association (Declaration of Helsinki)
are provided in the original referenced publications.
2.1. FTIR spectroscopy
FTIR Transmission spectra [33] were recorded using a Perkin Elmer
Spotlight 400 N FTIR imaging system. The system is equipped with an
AutoImage microscope system operating with a X40 Cassegrain objective.
FTIR spectra were collected in transmission mode over the nominal free-
scanning spectral range with an interferometer speed of 1.0 cm/s, using a
liquid nitrogen cooled mercury cadmium telluride (MCT-A) line detector,
with a pixel size of 25 mm x 25 mm and a spectral resolution of 4 cm1.
Background measurements of 120 scans per pixel were acquired on a
blank substrate, whereas 8 scans per pixel were recorded from the sample,
deposited on a CaF2 window and air dried before recording.
2.2. ATR-FTIR spectroscopy
ATR-FTIR spectra were recorded with either a Perkin Elmer Spotlight
400 N Universal Attenuated Total Reflectance (UATR) accessory [33] or a
Bruker Vector 22 equipped with a UATR module [34]. Sample
penetration is both wavenumber and sample dependent, but is typically
on the order of 1 mm. Prior to recording, a background spectrum was
recorded in air and automatically subtracted by the software.
2.3. Raman spectroscopy
A Horiba Jobin-Yvon LabRAM HR800 spectrometer was used for all
data presented. The spectrometer, housed in a stabilised room
temperature (18 C) environment, was coupled to an Olympus IX71
inverted microscope. A X60 water immersion objective (LUMPlanF1,
Olympus) was employed, providing a spatial resolution of 1–2 mm at the
sample, with a laser intensity of between 35–40 mW. The confocal hole
was set at 100 mm for all measurements, the specified setting for confocal
operation. Either a 532 nm [28,35–38] or 785 nm [33] laser was used as
source, and the system was spectrally calibrated to the 520.7 cm1
spectral line of silicon, by an automated instrument software routine, to
ensure consistency within and between datasets. In all experiments, a 300
lines/mm grating was used, providing a spectral dispersion of
approximately 1.5 cm1 per pixel with the 785 nm laser line, and
approximately 1.0 cm1 per pixel with the 532 nm laser line. The detector
used was a 16-bit dynamic range Peltier cooled CCD detector, and the
backscattered Raman signal was typically integrated for 2  30 s [33] or 3
 80 s [28,35–38] over the spectral range from 400 to 1800 cm1.
2.4. Materials
Gelatin (BDH, Ireland, 44045) [33] and glycine (Cooper, France) [34]
were analysed in both the powder form and after dilution in distilled
water to systematically varied concentrations. Solutions were either
analysed in the liquid state, or after deposition on a CaF2 window
(Crystran Limited, UK), or ATR crystal, after which they were air dried.
g globulins (G4386), albumin (A9511), urea (F3879) and b-carotene
(C97505 G) were purchased from Sigma Aldrich, Ireland. Solutions of
varying concentrations of urea (11000 mg/dL) were prepared in
distilled water by varying the concentrations over a physiologically
relevant range.
Methotrexate (MTX - A6770) and Busulfan (Bu - B058) [38] were
purchased from Sigma Aldrich, Ireland. Stock solutions of 0.1 mg/mL Bu
in methanol and 1 mM MTX in 0.1 M NaOH were prepared. Commercial
human serum was spiked with Bu and MTX over therapeutically relevant
concentration ranges, to achieve the final concentrations of (00.05 mg/
mL) for Bu and (0–100 mM) for MTX. The spiked concentrations of Bu in
serum are expressed in mg/mL and MTX in mM to be consistent with
previous studies [39,40].
Sterile filtered human serum from normal mixed pool (off the clot) was
purchased from TCS Biosciences (Ireland), or Sigma Aldrich (Ireland), or
was donated by the University Hospital (CHU) Bretonneau de Tours
(France), as part of the Cancéropôle du Grand-Ouest consortium [34]. D-
glucose (Fisher scientific, UK) was employed to spike serum samples over
the concentration ranges 0.0 mg/dL (control) - 220 mg/dL [41] and 440
mg/dL [35], to explore the dynamic range and sensitivities of the
respective spectroscopic techniques. The concentrations were selected to
encompass a wide range of physiological relevance to simulate
hypoglycaemia (<60 mg/dL), normal level (70/110 mg/dL) and
hyperglycaemia (>120 mg/dL), in order to evaluate the potential of
the protocols for clinically relevant human serum monitoring.
Depending on the experiment, samples were prepared either by
deposition of 20 mL of the serum on a CaF2 window (Crystran Limited,
UK), followed by air drying or filtration of 0.5 mL of the serum using
Amicon Ultra-0.5 mL centrifugal filter devices (Merck, Germany). In all
cases, the procedure for washing the centrifugal devices prior to serum
analysis was adapted from Bonnier et al. 2014 [42], according to
manufacturer’s guidelines. Either 3 kDa, 10 kDa or 50 kDa devices were
employed, individually or in combination, and typically 0.5 mL of the
serum was placed in the device and centrifuged at 14,000 x g for 30 min.
The filter device is then placed upside down in a new Eppendorf and spun
down at 1000 g for 2 min. Two fractions were obtained following each
filtration; the first representing constituents with a molecular weight
higher than the cut off point of the filter used (concentrate); the second
corresponding to the fraction passed by the membrane and collected in
the vial (filtrate).
For liquid state Raman measurements [28,35–38], the substrate used
was a Lab-Tek plate (catalogue number 154534) with a 0.160.19 mm
thick glass bottom, 1.0 borosilicate cover glass, purchased from Thermo
Fischer Scientific, Ireland.
2.5. Patient samples
Patient serum samples (n = 25) were donated by the University
Hospital CHU Bretonneau de Tours (France) [35,41]. Initially, the
samples were collected during routine blood check-ups, 1 mL of the vial
remains being provided for further spectroscopic analysis. Albumin, g
globulins (IgG, IgM and IgA), total protein, urea and glucose concentra-
tion levels were obtained by routine biochemical analysis using a
COBAS1 analyser (Roche Diagnostics), following the CHU guidelines for
routine biochemical analysis. Further patient details and serology
analyses have been provided in the original manuscripts [35,41].
Samples were fractionated, as appropriate, using Amicon Ultra-0.5 mL
centrifugal filter devices (Merck, Germany).
2.6. Spectral preprocessing
Depending on the analysis, different pre-processing steps were
performed using Matlab (Mathworks, USA). In the case of FTIR and
ATR-FTIR analyses shown, the spectra collected from the air dried whole
serum and the filtered samples (LMWF) were processed using baseline
correction (rubber-band) followed by vector normalisation [34].
H.J. Byrne et al. Clinical Spectroscopy 2 (2020) 100004
2
In the case of Raman analyses of spiked and patient serum samples,
smoothing of the raw data was done using the Savitzky–Golay method
(polynomial order of 5 and window 13) and the rubberband method [43]
was found to be appropriate to baseline correct the smoothed reference
spectra of all the analytes (used for EMSC, see below) and the smoothed
spectra of varying concentrations of albumin spiked in distilled water. An
adapted Extended Multiplicative Signal Correction (EMSC) algorithm,
details of which, as well as the (Matlab) source code are available in [44],
was applied to the raw dataset to remove the spectral interferents from the
data. The algorithm fits the measured spectra with a weighted sum of a
reference spectrum, spectra of the interferents to be subtracted, and a
baseline polynomial, also to be subtracted. EMSC was applied to remove
the underlying water spectrum from all the datasets. The weighting of the
contribution of water to each spectrum can also be used to scale the
analyte spectra, assuming a constant water contribution to all sample
spectra [35]. In the case of the analysis of total protein, g globulins and
albumin content [37], EMSC was also applied to remove the beta-
carotene. Since the Lab-Tek plate has a thin glass bottom, no glass
correction was required. Raman spectra of the pure serum, g globulin
(>100 mg/mL), albumin (>100 mg/mL), glucose (>450 mg/mL) and
urea (>100 mg/mL), b-carotene (>100 mg/mL) prepared with minimal
amount of water were used as reference spectra for EMSC.
2.7. Spectral analysis
The different data analysis steps were performed using Matlab
(Mathworks, USA). The principle methodology for quantitative analysis
of both spiked and human patient serum samples was that of Partial Least
Squares Regression (PLSR). PLSR is a multivariate statistical method
which aims to establish a model that relates the variations of the spectral
data to a series of relevant targets, in this case analyte concentrations, or
clinical parameters. The PLSR model attempts to elucidate factors which
account for the systematic majority of variation in predictors ‘X’ (spectral
data) versus associated responses ‘Y’ (target values of analyte concentra-
tion) [45]. PLSR enables the construction of a regression model, which
can then be used to predict the concentration of the target based on a
spectral measurement. Constructed based on the spectra of samples of
known analyte content, either solutions of varying concentrations in
distilled water or those of the patient serum, the model is then validated
using a rigorous cross validation procedure which evaluates its
performance in accurately predicting the analyte concentrations [35].
This approach involves randomly dividing the set of observations into
approximately equal size, 50 % of the spectral data randomly selected as
test set, while the remaining 50 % is used as the training set. The cross-
validation process is then repeated n times (the folds), whereby all
observations are used for both training and testing, and each observation
is used for testing exactly once. The results from the folds can then be
averaged to produce a single estimation. The Root Mean Square Error of
Cross Validation (RMSECV) is calculated from the n iterations to measure
the performance of the model for the unknown cases within the
calibration set. The correlation between the concentration and spectral
intensity is given by the R2 value. The number of latent variables used for
building the PLSR model is optimised by finding the value that is
equivalent to the minimum of the RMSECV. Using an unseen dataset, the
predictive capacity of the model can be verified by the Root Mean Square
Error of Cross Prediction (RMSEP).
3. Endogenous constituents of human serum
In describing their protocol for analysis of protein secondary structure
using FTIR, Yang et al. emphasise the importance of measuring such
biological macromolecules in an aqueous environment [46]. An optically
thin cell, whose thickness is defined by spacers of order <10 mm, with
windows of CaF2 or other such IR transparent material, is employed to
minimise the pathlength, and the contributions of the aqueous
environment, which overlap the amide I bands of the proteins (1640
cm1), can be digitally removed by subtraction. Relatively high
concentration protein concentration solutions (>3 mg/mL) are recom-
mended, to minimise the effects of under or over subtraction, which can
introduce artefacts to the analysis, and cautious recording of the
appropriate “blank”, of identical composition and under identical
conditions, is also emphasised.
Although similar transmission cells can also be employed in FTIR
microscopy, and notably have been employed for live cell analysis [47],
even at sub-cellular resolution [48], they are cumbersome for clinical
applications, and in biofluid measurement, a droplet deposited on a
suitable substrate is commonly analysed, in either transmission or (trans)
reflection mode. The water of an aqueous droplet deposited on a
transparent substrate is strongly absorbing, however, and therefore the
droplet is usually allowed to dry [49]. This process gives rise to the so-
called phenomenon of the “coffee-ring effect”, illustrated in Fig. 1 for the
case of a human serum droplet deposited onto a CaF2 disc, measured by
FTIR transmission [33]. In the specific case of human serum, this effect
should more correctly be referred to as the Vroman effect, named after the
Dutch haematologist, who studied the patterns and sequences of protein
deposition on surfaces from human blood serum [50]. The result of this
process is that the deposit is spatially highly physically inhomogeneous.
In the case of the undiluted serum droplet, the thickness of the deposit is
such that the absorbance is saturated in the centre and the edges, and the
averaged spectrum is dominated by the more transparent intermediate
regions. The deposit is also chemically inhomogeneous, as the different
serum proteins have differing affinities for adsorption onto the substrate
surface which results in varying rates of deposition and, even when
diluted, the measured absorbance spectrum is seen to vary significantly
across the cross section of the edge, resulting in apparent shifting of peaks,
as indicated by the dashed lines in Fig. 1 (Bottom) [33,51].
In Attenuated Total Reflection mode, the FTIR source is not
transmitted through the sample, but rather the sampling is by the
evanescent wave of a high refractive index crystal, such as diamond or
germanium, which extends 15 mm into a sample deposited on it [49].
Due to the low penetration depth, problems of saturation of the
absorbance by thick samples are largely avoided. Nevertheless, it should
be noted that, for dried samples deposited from a solution, the
quantitative relationship between the measured absorbance and the
analyte concentration in the source solution is rapidly lost, as the
deposited layer becomes thicker than the spatial extent of the evanescent
field. This is shown clearly in Fig. 2(a), for the case of ATR-FTIR spectra of
aqueous solutions and dried samples of glycine [34]. Whereas a linear,
Beer-Lambert relationship between measured absorbance and analyte
concentration is observed for the aqueous drops, this is lost for dried
deposits.
Furthermore, a comparison of the absorbance spectra of dried and
solvated analytes clearly illustrates a fundamental phenomenon, that the
change in the local molecular environment and potentially conformation,
as well as molecular aggregation, between the solvated and dried state
can significantly impact on the measured spectrum, as shown in Fig. 2(b),
also for the case of ATR-FTIR spectra of aqueous solutions and dried
samples of glycine [34].
The issues of sample inhomogeneity can be at least be partially
alleviated by micropipetting and/or ensuring the whole drop is sampled,
and there have been studies that show excellent specificity/sensitivity of
classification of diseased states using ATR-FTIR analysis of dried human
blood samples, for cancer detection, recently reviewed by Sala et al [52],
including ovarian cancer [53], breast cancer [54], as well as Alzheimer’s
disease [55,56]. Raman spectroscopic signatures were identified in
patients, with and without hepatocellular carcinoma (HCC) [57] and
signatures of extensive fibrosis in the liver, characteristic of the early
developmental stages of HCC have similarly been identified using ATR-
FTIR [58]. Ollesch et al. introduced automated sampling, robotically
spotting serum samples for high throughput FTIR measurements, in their
study of urinary bladder cancer [59]. Using as little as 1 mL of blood serum
for ATR-FTIR analysis, Hands et al. could distinguish between serum of
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brain tumour patients and controls, but also effectively predict tumour
grade, highlighting the great potential of ATR-FTIR spectroscopy of
human serum for determination of the severity of brain tumours [60].
Notably, in such classification tasks, a quantitative evaluation of any
one, or multiple, analytes is not required. In fact, multianalyte, dried
serum analysis has previously been reported using mid-infrared
spectroscopy in transmission mode, for the simultaneous quantitation
of eight serum analytes: total protein content, albumin, triglycerides,
cholesterol, glucose, urea, creatinine and uric acid [61]. More recently,
measuring samples of whole dried blood to demonstrate the ability of
ATR-FTIR identify and quantify malaria parasites, Roy et al. also spiked
samples with glucose (0–400 mg/dL) and urea (0–250 mg/dL), and
achieved relative RMSECVs of 16 % and 17 %, respectively, using a PLSR
analysis [62]. The study demonstrated the capacity of ATR-FTIR
spectroscopy to perform multianalyte/disease diagnosis, enabling the
simultaneous quantification of glucose and urea as well as malaria
parasitemia, using a single spectrum from a single drop of dried blood on a
glass microscope slide. Spalding et al. [63]were able to demonstrate
quantitative analysis of protein levels in pooled human serum samples
spiked with varying concentrations of human serum albumin (HSA) and
immunoglobulin G (IgG) using ATR-FTIR spectroscopy of dried samples.
Using a validated PLSR method, for the IgG spiked samples, a linearity of
R2 as high as 0.998 and a RMSEV of 0.49  0.05 mg/mL was achieved. To
demonstrate the potential for quantification in a clinical setting, analysis
of patient samples was performed, yielding R2 values of 0.992 and a
corresponding RMSEV of 0.66  0.05 /mL. Notably, the sample
preparation protocol was optimised to the measurement of 10 % diluted,
air dried samples.
Fig. 2. (a) Evolution of Area Under the Curve (AUC) of the 1360-1280 cm1 ATR-FTIR band as a function of glycine concentrations. The blue squares represent the
measurement performed from the sample in liquid form while the red dots correspond to the samples deposited after air-drying. The dotted line represents a linear fit to the
liquid form data. (b): Typical ATR IR spectrum collected from solution (‘wet’ samples) of glycine at 200 mg/mL deposited on the ATR crystal (A) and after air-drying (B).
No preprocessing has been applied. Additionally the dotted line represents the contribution of the water to the signal collected from the solution. The spectra have been
offset for clarity [34].
Fig. 1. Top: Infrared transmission image collected from a 20 mL drop of human serum after air drying with the corresponding spectra extracted from the labeled regions A,
B and C. Bottom: Infrared image collected for a 20 mL drop of human serum diluted 1/15 after air drying. Spectra collected in the region A, B and C are also presented,
arrows indicating peaks of significant difference, and dashed lines peak shifts. The spectra have been baseline corrected and vector normalised [33].
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The dynamic range of the constituent biochemical concentrations in
human serum remains challenging to quantification of their by many
techniques. By depleting the abundant high molecular weight proteins,
which otherwise dominate the signatures collected, the ability to monitor
changes in the concentrations of the low molecular weight constituents is
enhanced. The technique of fractionation is currently extensively used,
both in general serology [64–66] and in vibrational spectroscopic
analysis for improved quantitative analysis of low molecular weight
biomarkers [33,63,67].
The process of fractionation using centrifugal filtration for improved
quantitative analysis of low molecular weight biomarkers using ATR-IR
spectroscopy was specifically explored by Bonnier et al. [33,34,41]. A
single filtration using, for example a 10 kDa filter, produces two fractions;
a fraction which remains in the filter, of molecular weight greater than 10
kDa, which is concentrated by a factor of 5–10, and a filtrate, containing
the low molecular weight fraction <10 kDa. Using a cascade of multiple
filters (e.g. 100 kDa, followed by 50 kDa) results in multiple concentrates
and filtrates, for analysis of both the high and low molecular weight
fractions [37]. Initially employing glucose as a model spike in human
serum, it was demonstrated that fractionating the serum prior to ATR-
FTIR spectroscopic analysis of dried samples can considerably improve
the precision and accuracy of quantitative models based on PLSR [41]. In
the case of patient samples, previously clinically screened for glucose
levels, the Root Mean Square Error for the Validation set (RMSEV) was
improved by a factor of 5 following fractionation, yielding an average
relative error in the predictive values of 3 mg/dL (less than 1%).
Currently available clinical techniques offer significantly higher perfor-
mance in glucose level monitoring, with a standard deviation of 0.72 mg/
dL (0.04 mmol/L), and therefore it is difficult to conceive of ATR-FTIR
achieving better results. However, an RMSEV of 3.1 +/- 0.13 mg/dL,
places the precision of the approach of ATR-IR anslysis after fractionating
the human serum into a clinically relevant range of concentrations,
enabling, for example, the identification of patients with abnormal
glucose levels (either hypo- or hyper-glycaemia), in a rapid, low cost
fashion.
It should be noted that, because of the low sampling depth, it is also
possible to use ATR-FTIR for measurement of analytes in water solution.
Fig. 3 shows the example of gelatin in water solution, chosen as a model
compound, measured by ATR-FTIR [33]. Although the water absorption
masks that of the analyte in the high wavenumber regime (38002800 cm
1), gelatin features are clearly discernible in the fingerprint region, from
16001000 cm1, emerging with increasing concentration. The strength
of the absorption follows a Beer-Lambert like behaviour, as a function of
concentration, over the range of concentrations studied [33], as shown also
for the case of aqueous solutions of glycine, in Fig. 2 (a) [34]. However,
using the example of glycine spiked in serum, Bonnier et al. demonstrated
that removal of water, by drying, and the HMWF, by centrifugal filtration,
leads to an improvement of the sensitivity of the technique which allowed
to identifyblinded concentrations ofglycineupto50times lower compared
to measurements in the unfractionated liquid form [34].
Raman spectroscopy is potentially more amenable to the quantitative
measurement of analytes in aqueous solutions, as the water bands are
Fig. 3. Example of spectra recorded using the UATR accessory of the Perkin Elmer Spotlight 400 N. (I): high wavenumber region from water (black); gelatin at 400 mg/mL
(blue) and gelatin powder (Red). (II): finger print region from gelatin solutions at a concentration of 100 mg/mL (blue), 200 mg/mL (red), 300 mg/mL (green) and 400
mg/mL (black). For comparison, a spectrum of distilled water has been added (pink); No offset or correction has been applied [33].
Fig. 4. I: Spectra recorded using the 785 nm laser line. A: deionised water; B: gelatin 10 mg/mL; C: gelatin 25 mg/mL, D: gelatin 100 mg/mL E: gelatin 200 mg/mL, F:
Lyophilized gelatin and G: gelatin 10 mg/mL (2  150 s – X60 water immersion objective) after water subtraction (intensity x8 for comparison). Spectra have been offset
for clarity. II: Raman spectra recorded in the high wavenumber region of gelatin solutions at a concentration of 200 mg/mL (pink), 100 mg/mL (green), 25 mg/mL (red)
and 10 mg/mL (blue). For comparison, a spectrum of distilled water has been added (light blue) No offset or correction has been applied [33].
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relatively weaker, in comparison to IR. As an illustration, Bonnier et al.
performed a direct comparison of the techniques in aqueous solutions of
gelatin, human serum, and centrifugally filtered human serum (Fig. 4)
[33]. The ability to measure biomolecules in their native environment
eradicates potentially detrimental effects of aggregation on the spectral
profile, the need for spatial averaging over the area of a dried deposit, and
problems with saturation in optically thick samples. Measurement can be
performed by focussing the Raman source laser into the fluid (rather than
onto the surface) and long focal depths sample increased number of
analyte molecules, although there is a trade-off with the collection
efficiency of the object, which decreases with numerical aperture, in the
backscattering geometry. In a study to optimise the spectral acquisition
process, significant improved signal to noise/background was achieved
using an inverted geometry, in which the light was delivered to (and
collected from) the liquid sample on a CaF2 disc by a X60 immersion
objective, via a water droplet. Centrifugal filtration of the serum using a 3
kDa filter concentrated the bulk of the serum constituents, further
enhancing the spectroscopic signatures (Fig. 5). Parachalil et al. adapted
the set-up by introducing a commercial, cover slip (0.160.19 mm)
bottomed vesicle (Lab-Tek plate) as the substrate substrate [28]. The use
of glass precludes the use of a 785 nm laser [68,69], and thus a 532 nm
laser was chosen as the source This set-up also has the added advantage of
providing high quality, consistent Raman spectra from a sample volumes
as low as 1 mL.
As a direct comparison of the relative merits of the techniques,
Parachalil et al. [35] reproduced the sample fractionation protocol of
glucose spiked human serum and patient samples, and applied the same
PLSR analysis algorithm of the ATR-FTIR study of Bonnier et al. [41], to
Raman analysis of liquid samples. Measured in its aqueous form, the
primary background to the 10 kDa fraction of the (spiked or patient)
serum is that of water, which was removed using an adapted EMSC
algorithm [44] and the reference spectrum of glucose, measured in a high
concentration (>45 mg/mL) glucose solution (Fig. 6B). Also shown in
Fig. 6A is the reference Raman spectrum of urea, measured in a highly
concentrated solution (>100 mg/mL), the most prominent feature of
which (1000 cm1) is in close proximity to the strong features of
Fig. 5. Raman spectra recorded from human serum using a Horiba Labram HR 800. I: A: Using the inverted set up after centrifugal filtration; B: In the standard upright
position using a X60 immersion objective and C: Using the inverted microscope couple to the immersion X60 objective. II: Examples of different settings used for the
analysis of human serum using Labram HR 800. A: in the standard upright position; B: In the standard upright position using a X60 immersion objective and C: Using the
inverted microscope couple to the immersion X60 objective. III: A: Raman spectrum recorded using the inverted set up from distilled water; B: Raman spectrum recorded
from the Human serum; C: Raman spectrum recorded from the Human serum after ultrafiltration using the Amicon ultra-0.5 centrifugal filter devices 3 kDa. No offset or
correction has been applied [33].
Fig. 6. (A) Reference spectrum of urea (1000 mg/dL) and (B) Reference spectrum of glucose (45,000 mg/dL). The reduced spectral regions selected for PLSR analysis are
indicated by dotted lines in each spectrum [37].
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glucose, between 1000 and 1200 cm1. Although excellent PLSR
models were achievable for aqueous solutions of glucose, over the
extended concentration range of 01000 mg/dL, in the analysis of
glucose content of the spiked human serum, interference of urea features
in the PLSR analysis was clearly evident, and a satisfactory PLSR model for
glucose was only achievable for the reduced spectral range of 1030cm1
to 1400 cm1.
Fig. 7 illustrates the results of (A) the EMSC correction of Raman
spectra of the 10 kDa filtrate of the human patient serum samples, (B) the
process of varying the number of latent variables towards optimisation of
the PLSR model, (C) the PLSR model regression co-efficient, (D) the PLSR
model which shows (spectrally) predicted versus clinically measured
patient glucose levels. The spectral features of the regression co-efficient
match well the features of the reference Raman spectrum of glucose
(Fig. 6B), a critical consideration for confidence in the analysis process.
Table 1 compares the results of the analyses, clearly indicating that
Raman analysis provides a considerable (almost factor of 2) improvement
over the equivalent ATR-FTIR measurement. A potentially more
important differentiator between the two techniques is the requirement
for drying in the ATR-FTIR technique, adds considerably to the sampling
time and, of particular importance in a clinical context, the complexity of
the workflow [67,70].
It should be noted that a similar direct comparison of the techniques of
mid-IR and Raman spectroscopy, together with multivariate data
analysis, for the quantitative analysis of the serum of 247 blood donors
was previously performed by Rohleder et al. [71]. The IR analysis was
undertaken on dried droplets, whereas the Raman analysis was of the
liquid serum and/or serum filtrates. Under their investigation for the
quantification of glucose, urea, uric acid, LDL cholesterol, HDL
cholesterol, total protein, cholesterol and triglycerides, Raman and
mid-infrared spectroscopy delivered similar accuracies for the prediction
of physiologically relevant analyte levels, for the example of glucose,
RMSEP of 14.7 and 17.1 mg/dL for mid-infrared and Raman spectrosco-
py, respectively [71]. As long ago as 1999, Berger et al. undertook a
Raman microscopic analysis of whole human blood and serum samples in
liquid form, to simultaneously quantify the content of six target analytes,
namely glucose, cholesterol, triglyceride, urea, total protein and albumin
[72] For the case of glucose, an RMSEP of 26 mg/dL was achieved.
However, in neither case was fractionation of the serum undertaken to
deplete the HMWF analytes, and comparison of the results with those of
Fig. 7. (A): EMSC corrected Raman spectra of filtrate obtained after centrifugal filtration with 10 kDa filters of patient samples (5  52.25 mg/dL, 5  75.67 mg/dL, 5 
93.69 mg/dL, 5  210.81 mg/dL and 5  434.35 mg, offset for clarity) and the signature peaks are marked by asterisks, (B): Evolution of RMSECV of the data set, (C): plot
of PLSR coefficient with glucose features, (D): Predictive model built from the PLSR analysis. The value displayed in the PLSR model is an average of the concentration
predicted with the corresponding standard deviation calculated from the 20 iterations of the cross validation The RMSECV and R2 values were calculated as 1.84 mg/dL
and 0.84 respectively [35].
Table 1
Comparison of the results of ATR-FTIR [38] and Raman spectroscopic analysis [32] of patient sample set for monitoring the glucose levels.
Measurement type Concentration range (mg/dL) RMSECV(mg.dL1) Standard deviation (mg.dL1) R2
ATR-FTIR (Min-Max normalised) 61.25210 3.1 1.90 0.9957
Raman Spectroscopy 52.25210 1.6 2.31 0.91
52.25440 1.84 3.48 0.84
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Table 1 clearly demonstrate the benefits of serum processing.
More recently, Parachalil et al. further explored the suitability of
Raman microspectroscopy as a bioanalytical tool, when coupled with
fractionation and multivariate analysis, to analyse and quantify
constituent components of both the HMWF (total protein content, g
globulins and albumin) and LMWF (urea and glucose) of human patient
serum, in the native liquid form [37]. Multiple centrifugal filtration steps
were carried out, as illustrated schematically in Fig. 8, and the Raman
spectra of the resultant processed serum samples are shown in Fig. 9.
Using PLSR analysis, the g globulin and total protein analysis models,
based on unfiltered patient serum, produced R2 values of 0.88 and 0.82,
and RMSECV of 126 mg/dL and 115 mg/dL, respectively. Post
fractionation of the patient serum samples by centrifugal filtration using
100 kDa and 50 kDa filters, a similar analysis produced an R2 value of 0.91
and RMSECV of 90 mg/dL for albumin, which is comparable to the values
previously reported for a model of aqueous solutions of albumin over a
similar concentration range [28]. In the case of urea, R2 and RMSECV
values of 0.92 and 1.73 mg/dL were achieved for the low molecular
weight (<10 kDa) filtrate of patient samples, when the full spectral range
of 4001800 cm1 was employed. Reducing the spectral range of the
analysis to 800 cm1 to 1030 cm1 considerably improved the prediction
accuracy and sensitivity, resulting in an R2 value of 0.97 and RMSECV of
1.14 mg/dL. Table 2 summarises the results of the analyses. Notably,
using 532 nm as source, the spectrum of the whole serum is dominated by
features of carotenoid compounds (Fig. 9). Subtracting the carotenoid
contributions using the adapted EMSC protocol, the total carotenoid
content could be also be quantified, although in the study, total
carotenoid content was not available as a clinical parameter for PLSR
analysis.
4. Exogenous factors in human serum
4.1. Viremia
In addition to pathologically related variations of intrinsic constit-
uents of blood, detection, monitoring and quantification of exogenous
factors or agents is a potentially valuable clinical application of
vibrational spectroscopy, and, in this context, the screening of viral
infections may be a valuable strategic target. Although a virus replicates
only inside the living cells of an organism, it can be transported readily
throughout the body via the bloodstream (viremia), and in the case of, for
example, the malaria parasite and dengue virus, infection is via the blood
stream. Infection can also lead to the upregulation of several
biomolecules, transported in the blood, which are commonly used as
diagnostic markers [73]. Crucially, in addition to the detection of a viral
infection, quantification of viral load can be of critical importance for
monitoring disease progression, in terms of the health of the individual,
and containment of the outbreak. Serology based methods, Enzyme
Linked of Immunosorbent Assay (ELISA), which targets specific anti-
bodies arising in the blood from the response of the immune system due to
the viral infection, or more direct virus detection based methods such as
Polymerase Chain Reaction (PCR), are established clinical techniques,
but these modalities are usually complex, lengthy and costly [74–77],
suggesting a potential niche area for label free spectroscopic analysis.
There have been several reports of (Raman and IR) spectroscopic
signatures associated with human papilloma virus (HPV) infection,
particularly relevant for cervical cancer screening [78,79]. In HPV
infected cell lines, a semi-quantitative correlation was drawn between
expression of the protein p16 and level of viral infection level, and a PLSR
predictive model was developed, based on the FTIR signatures [80],
although it is notable that no signatures of the virus itself were
unambiguously identified. In blood based analysis, very notable and eye-
catching translational work by the group from Monash University, based
on the use of ATR –FTIR spectroscopy for the determination of malaria
parasitemia in whole blood samples, has been recently demonstrated in
field trials in austere environments, proving the robustness and capability
of serum biofluid [62].
Fig. 8. Schematic overview of steps in fractionation of patient serum samples to separate g globulin, albumin, and urea/glucose [37].
Fig. 9. Raman spectra of patient serum collected using Raman spectroscopy. (A)
whole serum, (B) concentrate from 50 kDa filtration and (C) filtrate from 10 kDa
filtration. Spectra have been off set for clarity [37].
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Saade et al. [81], demonstrated the potential of Raman spectroscopic
analysis of liquid sera samples to discriminate between normal and
hepatitis C patient samples. Ditta et al. [82] used a similar approach to
differentiate spectral markers of low, medium and high hepatitis C viral
loads. Saleem et al. [83] reported a Raman spectroscopic analysis of
dengue virus infection in (dried) human blood serum samples using
Raman spectroscopy, and although a PLRS model was constructed, with a
reported RMSEP of 0.0099 and correlation coefficient (R2) of 0.9998, it
was based only on normal/infected, rather than a continuous variation of
viral load. Khan et al. [84] used Raman spectroscopy, coupled with
support vector machine analysis, to diagnose dengue infection based on
positive IgM status, in samples of human serum dried on glass slides, with
a high degree of accuracy (85 %) and precision (90 %), and corresponding
sensitivity and specificity of 73 % and 93 %, respectively.
In a more quantitative approach, Bilal et al. [85] performed a Raman
spectroscopic analysis of dengue infected human serum samples in liquid
form, and, based on PLSR analysis of data of IgM positive and normal
human serum samples, established a prediction model with a correlation
co-efficient R2 of 0.929 and RMSECV for the entire predicted values of
10 %. Using the receiver operating characteristic curve (ROC)
approach, an accuracy of 96.67 %, a sensitivity of 90 % and a specificity
of 100 % were reported. In a similar approach, using Raman spectroscopy
coupled with PLSR analysis, Nawaz et al. [86] reported an RMSEP of 0.2
%, for hepatitis C viral load in liquid samples of human blood plasma, as
measured by the current clinical gold standard PCR. Although the study
was only performed on a patient cohort of 10, and the methodology
optimisation not explored extensively, the result justifies further
exploration of the technique for clinical translation.
The potential role of vibrational spectroscopy in the control and
monitoring of pandemic outbreaks is (at the time of writing) a very topical
proposition [87]. In the current case of COVID 19, the transmission of the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
understood to be largely respiratory, and so initial population screening
of, for example, nasopharyngeal aspirate may be most appropriate.
However, post infection screening for blood borne antibodies could play a
critical role in reintegration into society, post quarantine.
Table 2
Summary of the results obtained from the patient samples [34].
Analyte Analysis range Concentration range (mg/dL) R2 RMSECV (mg/dL) Standard deviation (mg/dL)
Total protein (whole serum) 4001800 cm1 42007900 0.82 115 5.7
g globulin (whole serum) 11501600 cm1 3291404 0.88 126 4.6
Albumin (HMWF) 4001800 cm1 26004780 0.90 90 1.2
Glucose (LMWF) 10301400 cm1 52.5434.2 0.84 1.8 3.5
Urea (LMWF) 4001800 cm1 2.5278.99 0.92 1.7 2.9
Urea (LMWF) 8001030 cm1 2.5278.99 0.97 1.1 2.5
Fig. 10. Reference spectrum of Bu used for EMSC correction. The chemical structure of Bu is shown in the inset. B: Reference spectrum of MTX used for EMSC correction.
The chemical structure of MTX is shown in the inset. C: PLSR coefficient plot of Bu (400-1800 cm1) in serum filtrate concentrations showing spectral features similar to
the Bu reference at 1097 cm-1 and 1453 cm1. D: PLSR coefficient plot of regression against MTX from 1200-1800 cm1 showing spectral features similar to the MTX
reference at 1351 cm1, and 1593 cm1. RMSECV were calculated to be 0.0003 mg/mL for Bu and 4.02 mM for MTX, respectively [38].
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4.2. Therapeutic drug monitoring
A further potential application area of clinical relevance for
vibrational spectroscopy is that of therapeutic drug monitoring (TDM).
TDM refers to the clinical practice of management of a patient's drug
dosage within a targeted therapeutic window, based on measurement of
concentration of the drug in the bloodstream at timed intervals. For drugs
with a narrow therapeutic range, such monitoring is essential to provide
individualised patient treatment, while maintaining the efficacy of drugs
and minimising drug toxicity and related adverse effects [25,88]. TDM
has also been increasingly advocated to improve the standard of
chemotherapy, in which side effects can be substantial and life
threatening [89–92]. The currently employed technique of chemothera-
peutic-dosage calculation, based on dose intensity and body surface area,
has been reported to be inaccurate for patients undergoing sustained
chemotherapeutic treatment [93,94]. In an era of rapidly increasing
healthcare costs, it is desirable to explore rapid, sensitive, and cost-
effective, point-of-care techniques for TDM, which could quantitatively
measure the serum concentration of drugs, such that the dosing strategy
can be tailored to the metabolism of an individual patient, for a
personalised therapeutic regime.
As a proof of concept study, the standardised, optimised methodology
of Parachalil et al. [35] was applied to determine the Limit of Detection
(LOD) and Limit of Quantification (LOQ) for TDM in spiked human serum,
using the examples of Busulfan (Bu), a cell cycle non-specific alkylating
antineoplastic agent, and Methotrexate (MTX), a chemotherapeutic agent
and immune system suppressant [38]. The Raman spectra of aqueous
solutions of the respective compounds, as well as their chemical
structures, are depicted in Fig. 10 (A and B). The drug concentration
ranges added to the human pooled serum as spikes were chosen to
encompass the recommended therapeutic ranges and toxic levels in
patients [38]. Centrifugal filtration of the spiked human pooled serum
with 10 kDa filters efficiently recovered the drug in the filtrate, prior to
performing Raman analysis. Predictive models were built by using PLSR,
the regression co-efficients of which matched well the Raman spectra of
the compounds, as shown in Fig. 10 (C &D), and values of LOD and LOQ
were calculated directly. The LOD calculated for Busulfan was
determined to be 0.0002  0.0001 mg/mL, 30–40 times lower than
the level of toxicity, enabling the application of this method in target dose
adjustment of Busulfan for patients undergoing, for example, bone
marrow transplantation. The LOD and LOQ calculated for Methotrexate
were 7.8  5 mM and 26  5 mM, respectively, potentially enabling high
dose monitoring.
5. Discussion
In the quest for strategic, target applications of vibrational
spectroscopy with achievable clinical translation, there has been much
debate over the relative merits of infrared absorption and Raman
scattering spectroscopies [1,2]. While issues of intrinsic spatial and
spectral resolution may be relevant to histo and cyto pathological
applications, the main consideration for applications to biofluid analysis
is that of the aqueous environment. The vibrational spectrum of water is
dominated by combinations of symmetric stretch (v1 3250 cm1),
asymmetric stretch (v33450 cm1) and bending (v21640 cm1) of the
OH bonds (Fig. 3), whose spectral distribution can be modulated by
local hydrogen bonding interactions [95]. The broad bands overlap with,
and can obscure, significant features of relevant biomolecules (e.g. Amine
A, CH2, CH3, OH in the high wave number region, and the Amide I band in
the low wavenumber region). OH bonds are highly polar, and are thus
very much more IR than Raman active, and therefore, in the frame of
reference of the water, Raman spectroscopy is significantly more sensitive
to the constituent components of biofluids than IR spectroscopy. It should
be stressed, however, that IR measurement, and indeed quantitative
analysis, in the aqueous environment is not impossible [33,34], but it has
been demonstrated that the quantitative analysis, of fractionated serum
samples by ATR-FTIR, is improved by precipitation of the analyte in the
form of a dried deposit [41].
Significant progress has been made towards the clinical translation of
ATR-FTIR platforms for diagnostic applications, based on analysis of
dried plasma/serum, some notable examples being for brain cancer
(recently reviewed by Sala et al. [52]), malaria [96] and Alzheimer’s
disease [55,56]. The potential of the technique is aided by increasingly
sophisticated data analysis techniques, based, for example on machine
learning algorithms [54], and the feasibility of ATR-FTIR analysis for
clinical screening of human serum for brain tumour diagnostics has been
subjected to a health economics study [97]. The process is readily
adaptable to automation, and tailor made, disposable and low-cost micro-
fabricated silicon substrates for use as ATR elements have been employed
to batch process serum sample measurements for cancer diagnostics, in a
clinical validation study [98].
Although ATR-FTIR of dried serum deposits has been demonstrated to
perform well for classification applications, the technique struggles in
terms of quantification of constituent analytes. As illustrated in Fig. 2(a),
the quantitative (Beer-Lambert) relationship between the measured
absorbance and the analyte concentration in the source solution is lost as
the deposit thickness becomes comparable with, or exceeds, the spatial
extent of the evanescent wave. The characteristics of the spectrum of the
constituent biomolecules themselves are also perturbed by the change in
the local environment, causing bathochromic and hypochromic shifts, as
shown for the example of glycine, in Fig. 2(b). Moreover, the degree to
which both these effects influence the measured spectrum can vary across
the extent of the inhomogeneous deposit (Fig. 1). Averaging over an
entire deposit serves to hide the effects, rather than eliminate them.
The arguments for the quantification of analytes in their native
aqueous environment therefore favours the use of Raman spectroscopy. A
number of studies have demonstrated the potential of the technique for
quantification of both high and low molecular weight serum constituents,
in the native aqueous environment, with a degree of accuracy at least as
high as, or higher, than IR analysis of dried samples [35,71,72,99]. For
both IR and Raman analyses, serum fractionation, to reduce the dynamic
range of molecular weights of the constituent analytes, has been
demonstrated to significantly enhance the sensitivity and accuracy of
the measurement [33,34,37]. Fractionation by centrifugal filtration also
increases the concentration of the fraction retained in the filter,
improving the sensitivity of liquid based measurements [28]. In the
application of such techniques, however, it is important to ensure the
fidelity of the process, in terms of separation of constituent biomolecules
purely based on their molecular weight. In a simulated plasma protein
mixture, fractionation using 100 kDa filters was seen to be ineffective in
separating the poorly soluble fibrinogen fraction from the albumin and
lower molecular weight proteins, necessitating the use of alternative
fractionation techniques, in this case, ion exchange chromatography
[28]. Bonnier et al. demonstrated the efficacy of the process of separating
high and low molecular weight constituents by centrifugal filtration of
human serum using a 10 kDa device [34]. Nevertheless, although they
have a molecular weight of < 10 kDa, the strong carotenoid signals
observed in the Raman spectra of patient serum samples, using 532 nm as
source, were still evident in the concentrate of 50 kDa filtration, and
undetectable in the 10 kDa filtrate (Fig. 9 [37]). Albumin has been shown
to have a high affinity for carotenoids, for which it plays a key role against
oxidative degradation [100], as well as some chemotherapeutic agents
such as doxorubicin [101], for which it aids in solubilisation and
transport. Therefore, although such centrifugal fractionation techniques
are commonly employed in serology [64–66], it is important to validate
their fidelity using, for example simulated spiking experiments [37], and
exploration of alternative fractionation techniques such as on exchange
chromatography [28] is warranted.
Raman microspectroscopy for analysis of aqueous human serum offers
a number of experimental options, towards optimisation of the technique.
Bonnier et al. undertook a systematic study of different microscope
geometries, concluding that an inverted geometry, using a X60 water
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immersion objective to focus a 785 nm laser source through the underside
of a CaF2 substrate gave the best performance [33]. A water droplet
between the objective and substrate provided improved optical coupling
of the source laser to the sample, and the backscattered Raman signal. The
laser focus in the liquid sample is beyond the plane of the substrate, and
the limited focal depth means that sample volumes as low as 1 mL can be
measured. Parachalil et al. demonstrated that the CaF2 substrate could be
replaced by a commercial, glass coverslip (0.160.19 mm) bottomed
vesicle (Lab-tek plate), more amenable to clinical translation, albeit using
a 532 nm as source [28], to avoid the intrinsic fluorescence of glass at 785
nm [68,69]. A similar set up was employed by Medipally et al. [102], who
used either 532 nm or 785 nm for analysis of blood plasma in a coverslip
bottomed 96 well plate, suggesting that fluorescence from the glass is not
an issue, under these conditions. They also demonstrated automated
analysis of multiple samples, and therefore the potential for a higher
throughout technique.
Choice of wavelength for Raman spectroscopy can also be influenced
by the analyte of interest. Although the majority of biomolecules are
transparent in the visible region of the spectrum, and so do not absorb or
fluoresce, some are intrinsically stronger Raman scatterers than others.
The complementarity of IR and Raman spectroscopy is based on the fact
that, while highly polar bonds (e.g. OH) are very strong in IR spectra,
polarisable moieties are strong in Raman spectroscopy [103]. This is
particularly the case for p-conjugated (unsaturated) bonds, and thus the
sharp phenyl alanine vibration at 1004 cm1 is seen prominently in any
Raman spectrum of tissue or cells, although it is not the predominant
protein residue. As the conjugation length is extended across sequential -C
= C- bonds, for example in carotenoids, the polarisability increases, and
with it the Raman cross section [104]. As the conjugation increases, so too
does the wavelength of the lowest energy optical absorption (HOMO-
LUMO), giving colour to the biomolecular constituents of skin (melanin),
blood (haemoglobin), and blood serum (carotenoids). When the
wavelength of the source laser matches, or is in close proximity to, the
absorption of an analyte, the Raman scattering is resonantly enhanced, by
up to several orders of magnitude. Thus, for example, residual blood
traces have been seen to dominate the 532 nm Raman analysis of cervical
smear samples [105], and carotenoids blood serum samples
[37,102,106]. Linear conjugated chains have strong electron vibrational
coupling, and therefore do not fluoresce strongly, and so such resonance
enhancement can be used to selectively enhance the Raman response of
the analyte of interest, or alternatively longer wavelengths can be chosen
to avoid the dominance of analytes which are not of interest. If the
spectrum of an unwanted interferent is known, it can be “digitally”
removed, as previously demonstrated for wax in tissue [107,108], glass
substrate contributions [68], and carotenoid signals in blood serum [37].
Analysis of carotenoid content in serum may, however, be of interest for
analysis of, for example, retinal health, characterisable by the carotenoids
lutein and zeaxanthin [109,110].
Proximity of the laser source to the absorption resonance of an analyte
can, however, be a double edged sword. Without considering any
potential photochemical effects, strong absorption of an analyte present
in high concentrations can result in a depletion of the laser intensity
before it comes to a focus, and a reduced Raman signal, which can also be
reabsorbed by the analyte, resulting in a loss of the (quantitative) linear
relationship between the measured Raman signal and the analyte [111].
Excited chromophores can also re-emit light as fluorescence or
phosphorescence, which can add significantly to the Raman background,
at times swamping the signal. For wavelengths above 500 nm, no such
chromophores exist amongst the endogenous constituents of human
serum, and no strong fluorescence is observable.
For applications of Raman spectroscopy for quantification of
exogenous agents, however, judicious choice of wavelength may be
appropriate. In the case of viremia, the virus itself is not unambiguously
identified, although it has been demonstrated that viral load can be
quantified on the basis of the changes to the spectral profile of the patient
serum. It may therefore be that the technique is sensitive to the effect,
rather than the root cause. Choice of wavelength is therefore subject to the
same considerations as analysis of endogenous serum constituents.
However, an important consideration for the analysis protocol in this case
is the regression algorithm. In cell cultures exposed to the drug cisplatin, it
was demonstrated that PLSR using targets of the drug concentration gave
different results to regression against the (sigmoidal) resultant cell
viability, interpretable as the effects of the initial chemical binding of the
drug in the nucleus, and the subsequent cellular response, respectively
[112,113]. In its simplest form, PLSR assumes a linear relationship
between regression target and spectroscopic response, but in monitoring
physiological effects in human serum as a result of exposure to exogenous
agents, more sophisticated data mining methodologies may be
[114,115].
In the case of TDM, choice of wavelength can be dependent on the drug
in question. The LOD and LOQ of an analyte in aqueous solution is
dependent on the baseline signal of the “blank”, with no analyte, and the
strength of the Raman signal of the analyte. Molecules such as
doxorubicin are highly absorbing and fluorescent at 532 nm, and so
should be measured at longer, off-resonant wavelengths such as 785 nm
[116,117], whereas shorter wavelengths are appropriate for other
chemotherapeutic agents such as busulfan and MTX [38], and choice of
wavelength could be chosen to decrease the LOD to clinically applicable
ranges.
Surface enhanced Raman spectroscopy is often cited as a route
towards significantly improved quantitative analysis of low molecular
weight analytes. Bonifacio et al. have examined in detail the applications
of colloidal SERS to analysis of human plasma and serum, and have
concluded that, due to adsorption on the surface, preventing the
formation of hotspots, intense and repeatable spectra are obtained only if
proteins are filtered out from samples [118]. Nevertheless, the technique
may be appropriate for highly sensitive detection and quantification of
small blood borne molecules, and its potential role in TDM was reviewed
in 2016 [39]. Using commercial SERS substrates, quantification of
imatinib in blood plasma over the concentration range of 123–5000 ng/
mL has been demonstrated [119]. However, although it has demonstrated
promising results in detecting drugs at low concentrations in biological
matrices [40,90], qualitative variations within the SERS substrate, and
interference of other biomolecules with the spectra, makes quantification
in clinical samples a challenging task [39].
Note, however, that for the study of busulfan and MTX, the values of
LOD and LOQ calculated are within therapeutically relevant ranges,
encouraging for the potential for clinical translation [38]. Note also, that
the fundamental rationale for TDM is to monitor the pharmacokinetics of
the drug, due to absorption, distribution, metabolism, and excretion, the
rate of which can vary significantly from individual to individual.
Monitoring the rates of change of the serum levels of a drug, rather than
the lowest depleted levels, may therefore be sufficient for effective TDM
[120].
In the case of proof-of-concept Raman spectroscopic analyses, the
majority have been performed using high specification, relatively
expensive, research grade, microscope based instruments. In terms of
initial capital costs, and field deployability, this makes the approach of
Raman potentially less attractive than ATR-FTIR. Nevertheless, more
compact, less expensive, but similarly high specification systems are
becoming increasingly available, which would reduce the initial capital
cost from hundreds, to less than a hundred, thousand Euro. Furthermore,
for measurement in liquid form, the microscope serves only as a light
delivery and collection vehicle, and significantly lower cost fiber based
and “portable” options may be viable alternative, reducing capital costs to
sim;euro;1020k, comparable to those of compact ATR-FTIR instru-
ments. Indeed, fiber based [121] and on-chip waveguide [122] systems
potentially offer routes towards further enhancement of signal to noise
ratios, and measurement sensitivity. The techniques of IR and Raman
spectroscopy, in different manifestations, may therefore be equally viable
candidates for clinical translation in terms of initial capital outlay, both
are bench top techniques, requiring no specific services in terms of voltage
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supply or cooling, each entails similarly minimal sample preparation, and
in an appropriately designed user interface, could be operated by a non-
specialist clinical technician, or general practitioner. Aspects of
automation and increased throughput are, to a greater or lesser extent,
similarly applicable to both techniques [52,67,102], although the ability
to measure in aqueous environment, without the need for drying, may be
significant in terms of clinical work-flow [70]. It should also be noted that
applications of such techniques are not limited to human serum, or even to
human biofluids, and may have potential in other fields such as veterinary
care [123].
6. Conclusions and future perspectives
Numerous studies have demonstrated the potential for vibrational
spectroscopy to quantitatively identify and monitor changes in concen-
trations of both endogenous constituents of human blood serum, and
endogenous agents, such as viruses and drugs, as well as their effects, in
both cases, within clinically relevant ranges. Because it lends itself more
naturally to measurement in the native aqueous environment, Raman
spectroscopy is a more attractive candidate for such clinical serological
applications. As is the case for many established clinical methodologies,
serum fractionation significantly enhances the sensitivity of the
measurement, but independent measurement of high and low molecular
weight fractions yields datasets which can be screened for multiple
analytes simultaneously, in a label free manner, making it a potentially
low-cost, rapid alternative to currently established clinical methods.
Many of the studies to date have been proof of concept, however, and
there has been little concerted, systematic optimisation of experimental
sampling conditions. Sample preprocessing, Raman source wavelength
and data analysis, are all factors which could be optimised to fine tune
performance. Patient cohort numbers have been relatively low, and to
date the influence of potential confounding factors such as diet and
medication have not been considered.
Nevertheless, the multiple proof-of-concept studies demonstrate the
potential for clinical translation of quantitative serum analysis using
vibrational spectroscopy, warranting larger, clinical scale trials, and in-
depth assessment of the associated clinical workflow, and health
economics.
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